Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

A Detailed Insight into Nanostructured Lipid Carriers: A Versatile Drug Delivery System

Author(s): Samarjit Ghosh, Triveni Tiwari, Upendra Nagaich and Neha Jain*

Volume 17, Issue 4, 2023

Published on: 29 August, 2022

Page: [284 - 306] Pages: 23

DOI: 10.2174/1872210516666220523121733

Price: $65

Abstract

The advent of technology provides a solution to various drug delivery-related problems by undertaking the development of a better drug delivery system, i.e., nano-sized drug delivery systems as they have shown huge prospects for effective delivery of drugs in the body. Nanostructured lipid carriers (NLCs) are such type of novel drug delivery system in which lipids of both solid and liquid types are used as a core for the disorganized matrix, which prevents the solid lipid crystallization and increases drug payload. They are generally composed of solid and liquid lipids, emulsifiers, drugs, and other various additives, which are selected based on purity, chemical stability, the concentration of materials required, compatibility, biodegradability, processing type, cost, and their regulatory status. Placing bioactives into nanostructured lipid carriers (NLCs) has enhanced pharmacokinetic characteristics by increasing therapeutic functionality and prolonging release from these carrier systems. In our opinion, the search involves two steps viz. fabrication strategies, production methods, and the impact of various types of substances on them, as well as the release mechanism and targeting modalities. In addition to other applications, the use of NLCs in gene therapy has marked a promising path for new and better drug delivery systems. Further development of various dosage forms using NLCs, like NLC based hydrogels, is being done for improving the overall aesthetic properties, leading to the desired therapeutic effect of the incorporated active. This review highlights several elements of NLCs, such as structural model and types, excipients utilized, factors affecting NLC production, preparation techniques, characterization, current applications, patents, challenges, and opportunities.

Keywords: Nanostructured lipid carriers, nanomedicine, nanotherapeutics, solid lipid, liquid lipid, surfactants.

« Previous Next »
Graphical Abstract

[1]
Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 2018; 103: 598-613.
[http://dx.doi.org/10.1016/j.biopha.2018.04.055] [PMID: 29677547]
[2]
Chao X, Zhao L, Ma N, Mou Y, Zhang P. Nanotechnology-based drug delivery systems for the improved sensitization of tamoxifen. J Drug Deliv Sci Technol 2021; 61: 102229.
[http://dx.doi.org/10.1016/j.jddst.2020.102229]
[3]
Rahdar A, Hajinezhad MR, Barani M, et al. Pluronic F127/Doxorubicin microemulsions: Preparation, characterization, and toxicity evaluations. J Mol Liq 2022; 345: 117028.
[http://dx.doi.org/10.1016/j.molliq.2021.117028]
[4]
Rahdar A, Hajinezhad MR, Nasri S, Beyzaei H, Barani M, Trant JF. The synthesis of methotrexate-loaded F127 microemulsions and their in vivo toxicity in a rat model. J Mol Liq 2020; 313: 113449.
[http://dx.doi.org/10.1016/j.molliq.2020.113449]
[5]
Mishra V, Bansal KK, Verma A, et al. Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. Pharmaceutics 2018; 10(4): E191.
[http://dx.doi.org/10.3390/pharmaceutics10040191] [PMID: 30340327]
[6]
Amaldoss MJ. Newton, Sukhjinder Kaur Solid lipid nanoparticles for skin and drug delivery. In: Alexandru MG, Ed. Nanoarchitectonics in Biomedicine. William Andrew 2019; pp. 295-334.
[http://dx.doi.org/10.1016/B978-0-12-816200-2.00015-3]
[7]
Rizwanullah M, Ahmad J, Amin S. Nanostructured lipid carriers: A novel platform for chemotherapeutics. Curr Drug Deliv 2016; 13(1): 4-26.
[http://dx.doi.org/10.2174/1567201812666150817124133] [PMID: 26279117]
[8]
Fang C-L, Al-Suwayeh SA, Fang J-Y. Nanostructured lipid carriers (nlcs) for drug delivery and targeting. Recent Pat Nanotechnol 2012; 7(1): 41-55.
[http://dx.doi.org/10.2174/1872210511307010041]
[9]
How CW, Abdullah R, Abbasalipourkabir R. Physicochemical properties of nanostructured lipid carriers as colloidal carrier system stabilized with polysorbate 20 and polysorbate 80. Afr J Biotechnol 2011; •••: 10.
[10]
Li Q, Cai T, Huang Y, Xia X, Cole SPC, Cai Y. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials (Basel) 2017; 7(6): E122.
[http://dx.doi.org/10.3390/nano7060122] [PMID: 28554993]
[11]
Vieira R, Severino P, Nalone LA, et al. Sucupira oil-loaded nanostructured lipid carriers (NLC): Lipid screening, factorial design, release profile, and cytotoxicity. Molecules 2020; 25(3): E685.
[http://dx.doi.org/10.3390/molecules25030685] [PMID: 32041134]
[12]
Patel P, Patel M. Nanostructured lipid carriers- a versatile carrier for oral delivery of lipophilic drugs. Recent Pat Nanotechnol 2021; 15(2): 154-64.
[http://dx.doi.org/10.2174/1872210514666200909154959] [PMID: 32912129]
[13]
Subramaniam B, Arshad NM, Malagobadan S, et al. Development and evaluation of 10-acetoxychavicol acetate (ACA)-loaded nanostructured lipid carriers for prostate cancer therapy. Pharmaceutics 2021; 13(4): 439.
[http://dx.doi.org/10.3390/pharmaceutics13040439] [PMID: 33804975]
[14]
Jhaveri A, Deshpande P, Torchilin V. Stimuli-sensitive nanopreparations for combination cancer therapy. J Control Release 2014; 190: 352-70.
[http://dx.doi.org/10.1016/j.jconrel.2014.05.002] [PMID: 24818767]
[15]
Obata Y, Tajima S, Takeoka S. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J Control Release 2010; 142(2): 267-76.
[http://dx.doi.org/10.1016/j.jconrel.2009.10.023] [PMID: 19861141]
[16]
Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49(16): 4373-84.
[PMID: 2545340]
[17]
Wang YC, Wang F, Sun TM, Wang J. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells. Bioconjug Chem 2011; 22(10): 1939-45.
[http://dx.doi.org/10.1021/bc200139n] [PMID: 21866903]
[18]
Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009; 71(3): 431-44.
[http://dx.doi.org/10.1016/j.ejpb.2008.09.026] [PMID: 18977297]
[19]
Dicheva BM, Koning GA. Targeted thermosensitive liposomes: An attractive novel approach for increased drug delivery to solid tumors. Expert Opin Drug Deliv 2014; 11(1): 83-100.
[http://dx.doi.org/10.1517/17425247.2014.866650] [PMID: 24320104]
[20]
Fomina N, McFearin C, Sermsakdi M, Edigin O, Almutairi A. UV and near-IR triggered release from polymeric nanoparticles. J Am Chem Soc 2010; 132(28): 9540-2.
[http://dx.doi.org/10.1021/ja102595j] [PMID: 20568765]
[21]
Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release 2009; 137(1): 63-8.
[http://dx.doi.org/10.1016/j.jconrel.2009.03.007] [PMID: 19303426]
[22]
Martinelli C, Pucci C, Ciofani G. Nanostructured carriers as innovative tools for cancer diagnosis and therapy. APL Bioeng 2019; 3(1): 011502.
[http://dx.doi.org/10.1063/1.5079943] [PMID: 31069332]
[23]
Hsu SH, Wen CJ, Al-Suwayeh SA, Huang YJ, Fang JY. Formulation design and evaluation of quantum dot-loaded nanostructured lipid carriers for integrating bioimaging and anticancer therapy. Nanomedicine (Lond) 2013; 8(8): 1253-69.
[http://dx.doi.org/10.2217/nnm.12.170] [PMID: 23384703]
[24]
Zheng S, Nguyen VD, Song SY, Han J, Park JO. Combined photothermal-chemotherapy of breast cancer by near infrared light responsive hyaluronic acid-decorated nanostructured lipid carriers. Nanotechnology 2017; 28(43): 435102.
[http://dx.doi.org/10.1088/1361-6528/aa847f] [PMID: 28783035]
[25]
Fernandes RS, Silva JO, Mussi SV, et al. Nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid as a theranostic agent: Evaluation of biodistribution and antitumor activity in experimental model. Mol Imaging Biol 2018; 20(3): 437-47.
[http://dx.doi.org/10.1007/s11307-017-1133-3] [PMID: 29043471]
[26]
Chen J, Chen H, Cui S, et al. Glucosamine derivative modified nanostructured lipid carriers for targeted tumor delivery. J Mater Chem 2012; 22(12): 5770-83.
[http://dx.doi.org/10.1039/c2jm15830b]
[27]
Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: A potential drug carrier for cancer chemotherapy. Lipids Health Dis 2012; 11(1): 159.
[http://dx.doi.org/10.1186/1476-511X-11-159] [PMID: 23167765]
[28]
Shah R, Eldridge D, Palombo E, Harding I. Lipid nanoparticles: Production, characterization and stability. 2015.
[29]
Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Adv Pharm Bull 2020; 10(2): 150-65.
[http://dx.doi.org/10.34172/apb.2020.021] [PMID: 32373485]
[30]
Kanwar R, Rathee J, Salunke DB, Mehta SK. Green nanotechnology-driven drug delivery assemblies. ACS Omega 2019; 4(5): 8804-15.
[http://dx.doi.org/10.1021/acsomega.9b00304] [PMID: 31459969]
[31]
Aditya NP, Macedo AS, Doktorovova S, et al. Development and evaluation of lipid nanocarriers for quercetin delivery: A comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). Lebensm Wiss Technol 2014; 59(1): 115-21.
[http://dx.doi.org/10.1016/j.lwt.2014.04.058]
[32]
Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles. Int J Nanomedicine 2007; 2(4): 595-607.
[PMID: 18203427]
[33]
Zhou J, Zhou D. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers. Drug Des Devel Ther 2015; 9: 5269-75.
[http://dx.doi.org/10.2147/DDDT.S90016] [PMID: 26425076]
[34]
Karn-Orachai K, Smith SM, Phunpee S, et al. The effect of surfactant composition on the chemical and structural properties of nanostructured lipid carriers. J Microencapsul 2014; 31(6): 609-18.
[http://dx.doi.org/10.3109/02652048.2014.911374] [PMID: 24861323]
[35]
Han F, Li S, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp 2008; 315(1-3): 210-6.
[http://dx.doi.org/10.1016/j.colsurfa.2007.08.005]
[36]
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure preparation and application. Adv Pharm Bull 2015; 5(3): 305-13.
[http://dx.doi.org/10.15171/apb.2015.043] [PMID: 26504751]
[37]
Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): Recent advances in drug delivery. J Pharm Investig 2013; 43(5): 353-62.
[http://dx.doi.org/10.1007/s40005-013-0087-y]
[38]
Beloqui A, del Pozo-Rodríguez A, Isla A, Rodríguez-Gascón A, Solinís MÁ. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. J Drug Deliv Sci Technol 2017; 42: 144-54.
[http://dx.doi.org/10.1016/j.jddst.2017.06.013]
[39]
Liu Y, Wang L, Zhao Y, et al. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin. Int J Pharm 2014; 476(1-2): 169-77.
[http://dx.doi.org/10.1016/j.ijpharm.2014.09.052] [PMID: 25280882]
[40]
Beloqui A, Solinís MÁ, Gascón AR, del Pozo-Rodríguez A, des Rieux A, Préat V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 2013; 166(2): 115-23.
[http://dx.doi.org/10.1016/j.jconrel.2012.12.021] [PMID: 23266764]
[41]
Sharma M, Sharma R, Jain DK, Saraf A. Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study. Int J Biol Macromol 2019; 135: 246-60.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.05.162] [PMID: 31128197]
[42]
Pinheiro M, Ribeiro R, Vieira A, Andrade F, Reis S. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des Devel Ther 2016; 10: 2467-75.
[http://dx.doi.org/10.2147/DDDT.S104395] [PMID: 27536067]
[43]
Lacatusu I, Mitrea E, Badea N, Stan R, Oprea O, Meghea A. Lipid nanoparticles based on omega-3 fatty acids as effective carriers for lutein delivery. Preparation and in vitro characterization studies. J Funct Foods 2013; 5(3): 1260-9.
[http://dx.doi.org/10.1016/j.jff.2013.04.010]
[44]
Guilherme VA, Ribeiro LNM, Tofoli GR, Franz-Montan M, de Paula E, de Jesus MB. Current challenges and future of lipid nanoparticles formulations for topical drug application to oral mucosa, skin, and eye. Curr Pharm Des 2017; 23(43): 6659-75.
[http://dx.doi.org/10.2174/1381612823666171122103849] [PMID: 29173149]
[45]
Karimi N, Ghanbarzadeh B, Hamishehkar H, Mehramuz B, Kafil HS. Antioxidant, Antimicrobial and Physicochemical Properties of Turmeric Extract-Loaded Nanostructured Lipid Carrier (NLC). Colloid Interface Sci Commun 2018; 22: 18-24.
[http://dx.doi.org/10.1016/j.colcom.2017.11.006]
[46]
Lin C, Chen F, Ye T, et al. A novel oral delivery system consisting in “drug-in cyclodextrin-in nanostructured lipid carriers” for poorly water-soluble drug: Vinpocetine. Int J Pharm 2014; 465(1-2): 90-6.
[http://dx.doi.org/10.1016/j.ijpharm.2014.02.013] [PMID: 24530388]
[47]
Mendes AI, Silva AC, Catita JAM, Cerqueira F, Gabriel C, Lopes CM. Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: Improving antifungal activity. Colloids Surf B Biointerfaces 2013; 111: 755-63.
[http://dx.doi.org/10.1016/j.colsurfb.2013.05.041] [PMID: 23954816]
[48]
Tian Z, Yi Y, Yuan H, et al. Solidification of nanostructured lipid carriers (NLCs) onto pellets by fluid-bed coating: Preparation, in vitro characterization and bioavailability in dogs. Powder Technol 2013; 247: 120-7.
[http://dx.doi.org/10.1016/j.powtec.2013.07.010]
[49]
Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol 2015; 20(3): 320-9.
[http://dx.doi.org/10.3109/10837450.2013.867445] [PMID: 24328553]
[50]
Elnaggar YSR, El-Massik MA, Abdallah OY. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles. Int J Nanomedicine 2011; 6: 3195-205.
[http://dx.doi.org/10.2147/IJN.S25825] [PMID: 22238508]
[51]
Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J 2021; 29(9): 999-1012.
[http://dx.doi.org/10.1016/j.jsps.2021.07.015] [PMID: 34588846]
[52]
Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: Part I oral bioavailability improvement. Eur J Pharm Biopharm 2014; 88(1): 160-8.
[http://dx.doi.org/10.1016/j.ejpb.2014.05.019] [PMID: 24878424]
[53]
Date AA, Vador N, Jagtap A, Nagarsenker MS. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: Fabrication, characterization and evaluation for oral drug delivery. Nanotechnology 2011; 22(27): 275102.
[http://dx.doi.org/10.1088/0957-4484/22/27/275102] [PMID: 21606564]
[54]
Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces 2007; 60(2): 174-9.
[http://dx.doi.org/10.1016/j.colsurfb.2007.06.011] [PMID: 17656075]
[55]
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol 2019; 51: 255-67.
[http://dx.doi.org/10.1016/j.jddst.2019.02.017]
[56]
Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: Versatile oral delivery vehicle. Future Sci OA 2016; 2(3): FSO135.
[http://dx.doi.org/10.4155/fsoa-2016-0030] [PMID: 28031979]
[57]
Luan J, Zheng F, Yang X, Yu A, Zhai G. Nanostructured lipid carriers for oral delivery of baicalin: in vitro and in vivo evaluation. Colloids Surf A Physicochem Eng Asp 2015; 466: 154-9.
[http://dx.doi.org/10.1016/j.colsurfa.2014.11.015]
[58]
Wang Q, Cheng H, Zhou K, et al. Nanostructured lipid carriers as a delivery system of biochanin A. Drug Deliv 2013; 20(8): 331-7.
[http://dx.doi.org/10.3109/10717544.2013.838716] [PMID: 24111887]
[59]
Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011; 43(3): 174-9.
[http://dx.doi.org/10.1016/j.ejps.2011.04.005] [PMID: 21530654]
[60]
Chaudhary S, Garg T, Murthy RSR, Rath G, Goyal AK. Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway. Int J Pharm 2015; 485(1-2): 108-21.
[http://dx.doi.org/10.1016/j.ijpharm.2015.02.070] [PMID: 25735668]
[61]
Hejri A, Khosravi A, Gharanjig K, Hejazi M. Optimisation of the formulation of β-carotene loaded nanostructured lipid carriers prepared by solvent diffusion method. Food Chem 2013; 141(1): 117-23.
[http://dx.doi.org/10.1016/j.foodchem.2013.02.080] [PMID: 23768336]
[62]
Sun B, Luo C, Li L, et al. Core-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxel. Colloids Surf B Biointerfaces 2016; 143: 47-55.
[http://dx.doi.org/10.1016/j.colsurfb.2016.02.065] [PMID: 27011346]
[63]
Zhang X, Qiao H, Zhang T, Shi Y, Ni J. Enhancement of gastrointestinal absorption of isoliquiritigenin by nanostructured lipid carrier. Adv Powder Technol 2014; 25(3): 1060-8.
[http://dx.doi.org/10.1016/j.apt.2014.02.012]
[64]
Huang J, Wang Q, Li T, Xia N, Xia Q. Nanostructured lipid carrier (NLC) as a strategy for encapsulation of quercetin and linseed oil: Preparation and in vitro characterization studies. J Food Eng 2017; 215: 1-12.
[http://dx.doi.org/10.1016/j.jfoodeng.2017.07.002]
[65]
Beh CY, How CW, Foo JB, Foong JN, Selvarajah GT, Rasedee A. Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers. Drug Des Devel Ther 2017; 11: 771-82.
[http://dx.doi.org/10.2147/DDDT.S123939] [PMID: 28352153]
[66]
Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. J Adv Res 2016; 7(3): 423-34.
[http://dx.doi.org/10.1016/j.jare.2016.03.002]
[67]
Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: Design, characterization, and in vivo study. Drug Deliv 2016; 23(4): 1326-34.
[http://dx.doi.org/10.3109/10717544.2014.975382] [PMID: 25367836]
[68]
Thatipamula R, Palem C, Gannu R, Mudragada S, Yamsani M. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru 2011; 19(1): 23-32.
[PMID: 22615636]
[69]
Carbone C, Campisi A, Musumeci T, Raciti G, Bonfanti R, Puglisi G. FA-loaded lipid drug delivery systems: Preparation, characterization and biological studies. Eur J Pharm Sci 2014; 52: 12-20.
[http://dx.doi.org/10.1016/j.ejps.2013.10.003] [PMID: 24514450]
[70]
How CW, Rasedee A, Manickam S, Rosli R. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: Characterization, stability assessment and cytotoxicity. Colloids Surf B Biointerfaces 2013; 112: 393-9.
[http://dx.doi.org/10.1016/j.colsurfb.2013.08.009] [PMID: 24036474]
[71]
Choi KO, Choe J, Suh S, Ko S. Positively charged nanostructured lipid carriers and their effect on the dissolution of poorly soluble drugs. Molecules 2016; 21(5): E672.
[http://dx.doi.org/10.3390/molecules21050672] [PMID: 27213324]
[72]
Severino P, Souto EB, Pinho SC, Santana MHA. Hydrophilic coating of mitotane-loaded lipid nanoparticles: Preliminary studies for mucosal adhesion. Pharm Dev Technol 2013; 18(3): 577-81.
[http://dx.doi.org/10.3109/10837450.2011.614250] [PMID: 21958059]
[73]
Sato MR, Oshiro Junior JA, Machado RTA, et al. Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis. Drug Des Devel Ther 2017; 11: 909-21.
[http://dx.doi.org/10.2147/DDDT.S127048] [PMID: 28356717]
[74]
Abdelwahab SI, Sheikh BY, Taha MME, et al. Thymoquinone-loaded nanostructured lipid carriers: Preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J Nanomed 2013; 8: 2163-72.
[http://dx.doi.org/10.2147/IJN.S44108] [PMID: 23818776]
[75]
Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010; 74(3): 474-82.
[http://dx.doi.org/10.1016/j.ejpb.2009.12.008] [PMID: 20060469]
[76]
Abdelbary G, Haider M. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate. Pharm Dev Technol 2013; 18(5): 1159-68.
[http://dx.doi.org/10.3109/10837450.2011.614251] [PMID: 21958084]
[77]
Pereira RR, Testi M, Rossi F, et al. Ucuùba (Virola surinamensis) fat-based nanostructured lipid carriers for nail drug delivery of ketoconazole: Development and optimization using box-behnken design. Pharmaceutics 2019; 11(6): E284.
[http://dx.doi.org/10.3390/pharmaceutics11060284] [PMID: 31212993]
[78]
Khan S, Baboota S, Ali J, Khan S, Narang RS, Narang JK. Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig 2015; 5(4): 182-91.
[http://dx.doi.org/10.4103/2230-973X.167661] [PMID: 26682188]
[79]
Beloqui A, Solinís MA, Delgado A, Évora C, Isla A, Rodríguez-Gascón A. Fate of nanostructured lipid carriers (NLCs) following the oral route: Design, pharmacokinetics and biodistribution. J Microencapsul 2014; 31(1): 1-8.
[http://dx.doi.org/10.3109/02652048.2013.788090] [PMID: 23631381]
[80]
Tran TH, Ramasamy T, Truong DH, Choi HG, Yong CS, Kim JO. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech 2014; 15(6): 1509-15.
[http://dx.doi.org/10.1208/s12249-014-0175-y] [PMID: 25035071]
[81]
Patil GB, Patil ND, Deshmukh PK, Patil PO, Bari SB. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach. Artif Cells Nanomed Biotechnol 2016; 44(1): 12-9.
[http://dx.doi.org/10.3109/21691401.2014.909820] [PMID: 24866725]
[82]
Neupane YR, Srivastava M, Ahmad N, Kumar N, Bhatnagar A, Kohli K. Lipid based nanocarrier system for the potential oral delivery of decitabine: Formulation design, characterization, ex vivo, and in vivo assessment. Int J Pharm 2014; 477(1-2): 601-12.
[http://dx.doi.org/10.1016/j.ijpharm.2014.11.001] [PMID: 25445972]
[83]
Li F, Weng Y, Wang L, He H, Yang J, Tang X. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm 2010; 393(1-2): 203-11.
[http://dx.doi.org/10.1016/j.ijpharm.2010.04.005] [PMID: 20385221]
[84]
Ganesan P, Ko HM, Kim IS, Choi DK. Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models. Int J Nanomedicine 2015; 10: 6757-72.
[http://dx.doi.org/10.2147/IJN.S93918] [PMID: 26604750]
[85]
Negi LM, Talegaonkar S, Jaggi M, et al. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. in vivo biodistribution, pharmacodynamic and hematological toxicity studies. Colloids Surf B Biointerfaces 2014; 123: 610-5.
[http://dx.doi.org/10.1016/j.colsurfb.2014.09.061] [PMID: 25454755]
[86]
Khajavinia A, Varshosaz J, Dehkordi AJ. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology 2012; 23(40): 405101.
[http://dx.doi.org/10.1088/0957-4484/23/40/405101] [PMID: 22983592]
[87]
Etxebeste-Mitxeltorena M, Moreno E, Carvalheiro M, et al. Oral efficacy of a diselenide compound loaded in nanostructured lipid carriers in a murine model of visceral leishmaniasis. ACS Infect Dis 2021; 7(12): 3197-209.
[http://dx.doi.org/10.1021/acsinfecdis.1c00394] [PMID: 34767359]
[88]
Zhang YW, Tu LL, Zhang Y, Pan JC, Zheng GL, Yin LN. Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis. Drug Deliv 2021; 28(1): 2534-47.
[http://dx.doi.org/10.1080/10717544.2021.2008054] [PMID: 34854788]
[89]
Sun M, Nie S, Pan X, Zhang R, Fan Z, Wang S. Quercetin-nanostructured lipid carriers: Characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces 2014; 113: 15-24.
[http://dx.doi.org/10.1016/j.colsurfb.2013.08.032] [PMID: 24060926]
[90]
Silva EL, Carneiro G, Caetano PA, et al. Nanostructured lipid carriers loaded with tributyrin as an alternative to improve anticancer activity of all-trans retinoic acid. Expert Rev Anticancer Ther 2015; 15(2): 247-56.
[http://dx.doi.org/10.1586/14737140.2015.1000868] [PMID: 25611812]
[91]
Bonaccorso A, Cimino C, Manno DE, et al. Essential oil-loaded nlc for potential intranasal administration. Pharmaceutics 2021; 13(8): 1166.
[http://dx.doi.org/10.3390/pharmaceutics13081166] [PMID: 34452126]
[92]
Chinsriwongkul A, Chareanputtakhun P, Ngawhirunpat T, et al. Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug. AAPS PharmSciTech 2012; 13(1): 150-8.
[http://dx.doi.org/10.1208/s12249-011-9733-8] [PMID: 22167418]
[93]
Mahoutforoush A, Solouk A, Hamishehkar H, Haghbin Nazarpak M, Abbaspour-Ravasjani S. Novel decorated nanostructured lipid carrier for simultaneous active targeting of three anti-cancer agents. Life Sci 2021; 279: 119576.
[http://dx.doi.org/10.1016/j.lfs.2021.119576] [PMID: 33965376]
[94]
Jiang T, Ma S, Shen Y, Li Y, Pan R, Xing H. Topical anesthetic and pain relief using penetration enhancer and transcriptional transactivator peptide multi-decorated nanostructured lipid carriers. Drug Deliv 2021; 28(1): 478-86.
[http://dx.doi.org/10.1080/10717544.2021.1889717] [PMID: 33641554]
[95]
Rodrigues da Silva GH, Geronimo G, García-López JP, et al. Articaine in functional NLC show improved anesthesia and anti-inflammatory activity in zebrafish. Sci Rep 2020; 10(1): 19733.
[http://dx.doi.org/10.1038/s41598-020-76751-6] [PMID: 33184457]
[96]
Al-Qushawi A, Rassouli A, Atyabi F, et al. Preparation and characterization of three tilmicosin-loaded lipid nanoparticles: Physicochemical properties and in vitro antibacterial activities. Iran J Pharm Res 2016; 15(4): 663-76.
[PMID: 28261309]
[97]
Kaur P, Garg T, Rath G, Murthy RSR, Goyal AK. Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design. Drug Deliv 2016; 23(6): 1912-25.
[http://dx.doi.org/10.3109/10717544.2014.993486] [PMID: 25544602]
[98]
Khalil RM, Abd-Elbary A, Kassem MA, Ghorab MM, Basha M. Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Pharm Dev Technol 2014; 19(3): 304-14.
[http://dx.doi.org/10.3109/10837450.2013.778872] [PMID: 23528038]
[99]
Grumezescu AM. Nanobiomaterials in galenic formulations and cosmetics: Applications of nanobiomaterials. New York: William Andrew 2016.
[100]
Chen Y, Zhou L, Yuan L, Zhang ZH, Liu X, Wu Q. Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int J Nanomedicine 2012; 7: 3023-32.
[http://dx.doi.org/10.2147/IJN.S32476] [PMID: 22787398]
[101]
Vairo C, Collantes M, Quincoces G, et al. Preclinical safety of topically administered nanostructured lipid carriers (NLC) for wound healing application: Biodistribution and toxicity studies. Int J Pharm 2019; 569: 118484.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118484] [PMID: 31260785]
[102]
Garg NK, Tandel N, Bhadada SK, Tyagi RK. Nanostructured lipid carrier-mediated transdermal delivery of aceclofenac hydrogel present an effective therapeutic approach for inflammatory diseases. Front Pharmacol 2021; 12: 713616.
[http://dx.doi.org/10.3389/fphar.2021.713616] [PMID: 34616297]
[103]
Chakole CM, Chauhan MK. Research progress of nanostructured lipid carriers in ocular drug delivery. Drug Deliv Lett 2021; 11(3): 203-19.
[http://dx.doi.org/10.2174/2210303111666210212143011]
[104]
Youssef A, Dudhipala N, Majumdar S. Ciprofloxacin loaded nanostructured lipid carriers incorporated into in-situ gels to improve management of bacterial endophthalmitis. Pharmaceutics 2020; 12(6): E572.
[http://dx.doi.org/10.3390/pharmaceutics12060572] [PMID: 32575524]
[105]
Lakhani P, Patil A, Wu KW, et al. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery. Int J Pharm 2019; 572: 118771.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118771] [PMID: 31669555]
[106]
Üner M, Yener G, Ergüven M. Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia. Mater Sci Eng C 2019; 103: 109874.
[http://dx.doi.org/10.1016/j.msec.2019.109874] [PMID: 31349508]
[107]
Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: A useful target for cancer therapy. J Membr Biol 2014; 247(4): 291-307.
[http://dx.doi.org/10.1007/s00232-014-9637-0] [PMID: 24573305]
[108]
Zhang B, Zhang Y, Yu D. Lung cancer gene therapy: Transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery. Oncol Rep 2017; 37(2): 937-44.
[http://dx.doi.org/10.3892/or.2016.5298] [PMID: 27959442]
[109]
Dos Santos Rodrigues B, Lakkadwala S, Kanekiyo T, Singh J. Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. Int J Nanomedicine 2019; 14: 6497-517.
[http://dx.doi.org/10.2147/IJN.S215941] [PMID: 31616141]
[110]
Hsueh YS, Shyong YJ, Yu HC, et al. Nanostructured lipid carrier gel formulation of recombinant human thrombomodulin improve diabetic wound healing by topical administration. Pharmaceutics 2021; 13(9): 1386.
[http://dx.doi.org/10.3390/pharmaceutics13091386] [PMID: 34575462]
[111]
Nordin N, Yeap SK, Zamberi NR, et al. Characterization and toxicity of citral incorporated with nanostructured lipid carrier. PeerJ 2018; 6: e3916.
[http://dx.doi.org/10.7717/peerj.3916] [PMID: 29312812]
[112]
Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 27-40.
[http://dx.doi.org/10.3109/21691401.2014.909822] [PMID: 24813223]
[113]
Rodrigues da Silva GH, Moura LD, Carvalho FV, et al. Antineoplastics encapsulated in nanostructured lipid carriers. Molecules 2021; 26(22): 6929.
[http://dx.doi.org/10.3390/molecules26226929] [PMID: 34834022]
[114]
Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics 2020; 12(3): E288.
[http://dx.doi.org/10.3390/pharmaceutics12030288] [PMID: 32210127]
[115]
Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release 2017; 264: 306-32.
[http://dx.doi.org/10.1016/j.jconrel.2017.08.033] [PMID: 28844756]
[116]
Tongqian C, Chandra V, Kurt V, Weimin W, Zhang YE. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules. 2008.
[117]
Cornelia K, Marc M. Nanonized testosterone formulations for improved bioavailability. 2010.
[118]
Ulagaraj SC. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening. European Patent EP2054036B1, 2009.
[119]
ROLF P. Nanocrystals for use in topical cosmetic formulations and method of production thereof. U.S. Patent No. 9,114,077, 2015.
[120]
Luisa BM, Gaetano G, Fabiola CE, Filippo D. Nanostructured lipid carriers containing riluzole and phamaceutical formulations containing said particles. U.S. Patent Application No. 12/308,932, 2010.
[121]
Ka-Wang WK, Jonathan W, Jared VG, Frank LS. Antibody bound synthetic vesicle containing molecules for deliver to central and peripheral nervous system cells. US Patent US20110097392A1, 2011.
[122]
Lluis VPJ, Raquel DG, Alfonso FB. Lipid nanoparticle capsules. U.S. Patent Application No. 13/636,909, 2013.
[123]
Arma T, Sulaiman RH, Bustamam AA, Wunhow C, Yeap SK. A composition for treating leukemia. WO2014123406A1, 2014.
[124]
Duran CNE, Pinto DAX. Method for producing nanostructured lipid carriers on triblock copolymers, nanostructured lipid carriers thereby produced, and uses thereof. WO/2016/065444, 2016.
[125]
Cheng Z, Ling Hui, Jingming Z, Taoyan Mao. Nanostructure lipid carrier coated with sun-screening agent and preparation method and application thereof. CN 107349116 A, 2017.
[126]
Cuiyan HAN, Shanshan Jin, MA Xiaoxing, Chang Liu, Cheng Y, Xiaoyu SUI, et al. Roxithromycin-loaded nanostructure lipid carrier gel and preparation method thereof. CN 105534881 A, 2016.
[127]
Domenico F, Jonathan C, Leana R, Keegan M. Nanostructure lipid carrier delivery system, composition, and methods. WO 2021/168573 A1, 2021.
[128]
Qing Y, Jinxi N, Ning Cai, Y Ling, Shuang Li. Pulullan-modified ginsenoside Rg3 nanostructure lipid carrier and preparation method thereof. CN 113262310 A, 2021.
[129]
Khan AA, Mudassir J, Akhtar S, Murugaiyah V, Darwis Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: Statistical optimization, in vitro and in vivo evaluations. Pharmaceutics 2019; 11(2): E97.
[http://dx.doi.org/10.3390/pharmaceutics11020097] [PMID: 30823545]
[130]
Anwar W, Dawaba HM, Afouna MI, Samy AM, Rashed MH, Abdelaziz AE. Enhancing the oral bioavailability of candesartan cilexetil loaded nanostructured lipid carriers: In vitro characterization and absorption in rats after oral administration. Pharmaceutics 2020; 12(11): E1047.
[http://dx.doi.org/10.3390/pharmaceutics12111047] [PMID: 33142816]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy